1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study

Abstract

In RATIONALE-303 (NCT03358875), TIS significantly improved overall survival (OS) vs TAX in the intent-to-treat population (ITT) at the interim analysis (IA). TIS was later approved in China for advanced or metastatic NSCLC after progression on prior platinum-based chemotherapy. At the final analysis (FA), the co-primary endpoint of OS in the programmed death-ligand 1 (PD-L1, VENTANA SP263 assay) tumor cell ≥ 25% population was met, and TIS continued to improve OS compared with TAX in the ITT. Here we report FA results from the Asian vs non-Asian subgroups.